Quick answer
NEO is an implantable brain-computer interface that decodes electrical signals from the brain's surface to help people with severe spinal cord injury regain hand grasp. It received China's — and the world's — first regulatory approval for an invasive BCI device in March 2026. On 13 July 2026, Fudan University's Huashan Hospital wrote the first post-approval prescription and performed the world's first implantation after approval [1][2][3].
Key takeaways
- NEO was approved by China's NMPA on 13 March 2026 as the world's first approved invasive BCI Class III medical device [3].
- The first patient, Mr Xu, injured his spinal cord in a car crash 10 years ago and had limited hand grasp; his injury (C3–C6) fit the device's indication [2].
- NEO reads epidural EEG signals, identifies movement intention, and links the brain to an external device that compensates for hand grasp [1].
- The Huashan team used functional MRI and cortical simulation to plan electrode placement, navigation for precision, and electrophysiology to confirm function [2].
- In the registrational study, 11 hospitals implanted 32 patients, with a 100% clinical response in grasp function under BCI assistance [4].
The case and the technology
Severe spinal cord injury often leaves hand function impaired, and drugs and conventional rehabilitation have limits. NEO is designed for this gap: electrodes placed on the dura (outside the brain) record signals, software decodes grasp intent, and an external device carries out the movement, so the patient can grasp again [1][2].
The surgery relied on careful planning: functional MRI and cortical modelling located the target, intraoperative navigation guided precise electrode placement, and electrophysiological checks confirmed the signal. Intraoperative testing showed stable, good-quality epidural EEG signals, and the patient was stable after surgery [1][2].
What was reported
The programme is led by Huashan Hospital president Mao Ying's neurosurgery team, which ran the registrational trial before approval. After approval the hospital completed medical-insurance price filing and NEO was included in Shanghai's commercial supplementary insurance, helping patients afford it [3][4].
This is the first real-world use of an approved device, not a new trial. The 100% grasp-response figure comes from the 32-patient registrational study; long-term durability, real-world benefit and cost will be tracked as more patients are treated [2][4].
The condition in context: spinal cord injury
Spinal cord injury often causes permanent loss of hand and limb function, and restoring grasp is a major rehabilitation goal.
| Region | What the data shows | Source |
|---|---|---|
| Worldwide | Hundreds of thousands of people suffer spinal cord injury each year, often with lasting disability [5]. | World Health Organization [5] |
| China | China has over 3.7 million people with spinal cord injury, with about 90,000 new cases a year [2]. | Media / hospital reports [2] |
| The gap | Drugs and conventional rehabilitation have limits for severe hand impairment, motivating BCI compensation [1]. | CCTV / hospital [1] |
Because hand grasp is central to self-care, even partial restoration can meaningfully change daily life — which is why an approved BCI device draws attention [1][5].
Why it matters
| For the patient | What the report suggests | Source |
|---|---|---|
| Restored function | BCI-assisted grasp helped all 32 trial patients respond [4]. | [4] |
| Access | Approval plus insurance inclusion moves BCI from lab to clinic [3]. | [3] |
| Caution | It is for specific injury levels; surgery is invasive and long-term data are still accruing [2][4]. | [2][4] |
Availability and limits
- This is an editorial summary of government, hospital and media reports, not an independent clinical assessment or a booking channel [1][2][3].
- NEO is approved only for its registered indication (severe spinal cord injury with hand impairment); not all injuries qualify [2].
- Implantation is invasive surgery requiring multidisciplinary planning and expert centres [2].
- Long-term safety, durability and real-world benefit are still being collected [4].
- Burden figures describe spinal cord injury generally and come from WHO, not this device [5].
What to ask before booking
| Question | Why it matters |
|---|---|
| Does my injury level and function fit NEO's indication? | Only certain cervical injuries qualify; ask for a specialist assessment [2]. |
| Is NEO available and covered by insurance? | Approval and coverage are new; availability varies [3]. |
| Which department handles foreign patients, and in what language? | Huashan is a working hospital we do not book; confirm international-department coordination and language support. |
| What does rehabilitation and follow-up involve? | BCI use requires training and monitoring; plan visits accordingly [2]. |
Questions patients ask
What is NEO?
An implantable brain-computer interface that records epidural brain signals, decodes hand-movement intention, and drives an external device to help spinal-cord-injury patients grasp [1][2].
What was the world-first here?
China's NMPA approved NEO in March 2026 as the world's first invasive BCI Class III device; on 13 July 2026 Huashan Hospital wrote the first prescription and performed the world's first post-approval implantation [1][3].
How well did it work in the trial?
Across 11 hospitals and 32 patients, the clinical response in grasp function under BCI assistance was 100% [4].
Who is eligible?
Patients with severe spinal cord injury and hand impairment within the device's registered indication; the first patient had a C3–C6 injury [2].
Is this relevant to international patients considering BCI care in China?
It is useful context for China's BCI access. Huashan is a working hospital we do not book — but it receives overseas enquiries; contact its international department directly and confirm candidacy, language support and logistics [4].